June 18, 2025 - The highly anticipated 2024 Journal Citation Reports (JCR) were officially released today, marking a significant achievement for Current Molecular Pharmacology (CMP). The journal's 2024 Impact Factor has increased to 2.9, with a five-year Impact Factor of 3.1, successfully advancing to the Q2 zone in the PHARMACOLOGY & PHARMACY category. This accomplishment signifies a notable enhancement in CMP's academic influence and recognition.
CMP is dedicated to publishing the latest advancements in cellular and molecular pharmacology, covering a broad range of topics within the field and is indexed by major databases including SCIE, Index Medicus, PubMed, Google Scholar, Medline, EBSCO, and Scopus.
The promotion to the Q2 zone in the PHARMACOLOGY & PHARMACY category, with a subject ranking of 150 out of 352, indicates a further increase in CMP's recognition and influence within its field. The BIOCHEMISTRY & MOLECULAR BIOLOGY category remains stable in the Q3 zone, ranked 182 out of 319, providing a higher-quality platform for academic exchange and knowledge transformation.
CMP Journal sincerely appreciate the long-term trust, support, and affection from our global editorial board, peer reviewers, authors, and readers. They warmly invite more researchers to submit their outstanding research findings to CMP, jointly advancing the field of molecular pharmacology.
The CMP team looks forward to using its new status in the Q2 zone of pharmacology as a springboard to continue to delve deeper into academia and contribute more to the field's development.